All In Biotech

Drug Trial Radar · NCT07010835

Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus

A Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of YK012 in the Treatment of Moderate to Severe Systemic Lupus Erythematosus

Last checked: Nov 19, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

189

Planned (sponsor's estimate)

Start

Aug 25, 2025

Primary completion

Jun 2027

Study completion Dec 2028

Sponsor

Lead sponsor
Excyte Biopharma LtdIndustry
Sponsor type
Industry
First posted
Jun 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of YK012 in participants with Moderate to Severe Systemic Lupus Erythematosus (SLE).

Conditions

  • Systemic Lupus Erythematosus (SLE)

Interventions

  • YK012Drug

    YK012 is a bispecific antibody targeting CD19 and CD3.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ib dose escalation stage: Dose Limiting Toxicity (DLT)Time frame: From the first infusion of YK012 to Day 28 post first infusion
  2. Adverse Event (AE)Time frame: From the first infusion of YK012 to the end of trial at 48 weeks
  3. Severe Adverse Event (SAE)Time frame: From the first infusion of YK012 to the end of trial at 48 weeks
  4. Ib dose expansion stage and phase II: SRI-4 (Systemic Lupus Erythematosus Responder Index-4) response ratesTime frame: From the first infusion of YK012 to the end of trial at 48 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.